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The genetic background of severe early-onset obesity is still incompletely understood. 
Deletions at 2p25.3 associate with early-onset obesity and variable intellectual disability. 
Myelin-transcriptor-factor-1-like (MYT1L) gene in this locus has been proposed a candidate 
gene for obesity. We report on a 13-year-old boy presenting with overweight already at 1 year 
of age (body mass index (BMI) Z-score +2.3) and obesity at 2 years of age (BMI Z-score 
+3.8). The patient had hyperphagia and delayed neurological, cognitive and motor 
development. He also had speech delay, strabismus, hyperactivity and intellectual disability. 
Brain MRI was normal. The parents and sister had normal BMI. Whole-genome sequencing 
identified in the index patient a novel de novo frameshift deletion that introduces a premature 
termination of translation NM_015025.2(MYT1L): c.2215_2224delACGCGCTGCC, 
p.(Thr739Alafs*7) in MYT1L. The frameshift variant was confirmed by Sanger sequencing. 
Our finding supports the association of MYT1L mutations with early-onset syndromic obesity. 
The identification of novel monogenic forms of childhood-onset obesity will provide insights 
to the involved genetic and biologic pathways. 
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    INTRODUCTION 
Genetic and molecular mechanisms underlying severe obesity are still incompletely 
understood; to date, disease-causing genes have been identified in only 24% of the syndromic 
forms of obesity (Kaur, de Souza, Gibson & Meyre, 2017). 
Deletions in 2p25.3 have been reported in several patients with intellectual disability 
and obesity (Bonaglia, Giorda & Zanini, 2014; De Rocker et al., 2015, Doco-Fenzy et al., 
2013, Stevens et al., 2011). Myelin-transcription-factor-1-like (MYT1L) falls within the 
deleted region and has been proposed as a candidate gene for obesity and intellectual 
disability (De Rocker et al., 2015). In line with this, a recent study identified de novo single 
nucleotide variants (SNVs) in MYT1L in patients with intellectual disability and variable 
obesity (Blanchet et al., 2017).  
MYT1L, encoded by MYT1L, belongs to the myelin transcription factor family and is 
expressed in the developing brain (De Rocker et al., 2015). Although the exact functions in 
the brain are unclear, MYT1L is known to regulate neuronal differentiation by repressing 
expression of non-neuronal genes and negative regulators of neurogenesis, and inducing pro-
neuronal genes (Kepa et al., 2017; Mall et al., 2017).  
We present a boy with intellectual disability, hyperphagia and severe early-onset 
obesity. Whole-genome sequencing (WGS) of the patient and his first-degree relatives 
identified a novel de novo frameshift deletion p.(Thr739Alafs*7) in MYT1L in the index 
patient. 
    CLINICAL REPORT 
This study was approved by the Institutional Research Ethics Committee and a written 
informed consent was obtained from all study participants and in case of minors, from their 
legal guardians. The index patient is a 13-year-old boy who was born at 37 weeks of gestation 
to unrelated healthy parents of Finnish descent. Pregnancy and delivery were uncomplicated 




and birth measurements were normal: weight of 3.38 kg (+0.1 SD), length 50 cm (+0.1 SD) 
and OFC 33 cm. Already at 12 months he was overweight with weight 12.2 kg (+2.2 SD) and 
length 77.6 cm (+0.8 SD) (body mass index (BMI) 20.3 kg/m2, BMI Z-score +2.3) and by 2 
years his BMI Z-score had increased to +3.8 (weight +3.5 SD, length +1.1 SD) (Figure 1a). 
Parents reported hyperphagia, food seeking behavior, and impaired satiety. Presently at the 
age of 13.8 years, he is obese with weight 82.1 kg and height 163.1 cm (BMI 31 kg/m2, BMI 
Z-score +2.8), (Figure 1b), and waist circumference 104.5 cm. His parents have normal 
weight (mother’s BMI 23 kg/m2 and father’s 25 kg/m2). His 9-year-old sister has normal BMI 
(Z score +1.6) and normal development. 
In addition to severe obesity, his neurological, cognitive and motor development were 
delayed. He presented with delayed speech, clumsiness, problems with balance, and 
strabismus. He was diagnosed with attention deficit and hyperactivity but had no aggressive 
behavior. He did not present with any dysmorphic features. Brain MRI at 4 years was normal 
and showed no hypothalamic or pituitary pathology. An electroencephalography EEG was 
also normal. He attends a special needs school.  
Laboratory investigations during childhood excluded hypothyroidism, hypercortisolism, 
and metabolic abnormalities. Fasting blood concentrations of glucose, insulin, cholesterol, 
and triglycerides were within normal range. Karyotype and screening for Prader-Willi and 
Fragile-X syndromes were normal.  
Array comparative genomic hydridization (aCGH) analysis was performed and no copy 
number variants (CNVs) that could explain the phenotype were detected. We performed WGS 
on genomic DNA from the index, both parents and the healthy sibling. Sample library 
preparation, sequencing, and primary bioinformatics were performed at the Science for Life 
Laboratory, Stockholm. Analysis of raw data was done as previously described (Costantini et 
al., 2018). We filtered variants that fit into de novo, compound heterozygous or autosomal 




recessive inheritance pattern and excluded variants with allele frequency of 0.5% and higher 
in 1000 Genomes Project (http://www.internationalgenome.org), Exome Aggregation 
Consortium (http://exac.broadinstitute.org), the Genome Aggregation Database 
(http://gnomad.broadinstitute.org), the SweGen dataset for genetic variations in the Swedish 
population (https://swegen-exac.nbis.se), and the Sequencing Initiative Suomi project (SISu) 
for genetic variants in the Finnish population (http://sisuproject.fi). We only included 
nonsynonymous variants, indels, and putative splice site variants for further consideration.  
The potential pathogenicity of the variants was assessed with Combined Annotation 
Dependent Depletion (CADD), polymorphism phenotyping (PolyPhen), sorting intolerant 
from tolerant (SIFT) prediction scores, and MutationTaster2. 
The WGS data analysis identified a novel heterozygous de novo frameshift deletion 
NM_015025.2(MYT1L): c.2215_2224delACGCGCTGCC, p.(Thr739Alafs*7) in exon 15 of 
MYT1L (Figure 2a,b). We confirmed the frameshift mutation with Sanger sequencing (Figure 
2c). The mutation was absent in the parents and sibling (Figure 2d). This frameshift variant 
has not been previously reported in the above-mentioned databases but is found in 1 out of the 
8696 in the African population in Genome Aggregation Database gnomAD 
(http://gnomad.broadinstitute.org). MutationTaster2 predicted the deletion as disease-causing. 
No other potential disease-causing variants were identified for the assumed inheritance 
patterns. 
DISCUSSION 
We describe a novel de novo MYT1L mutation in a patient with early-onset obesity, 
hyperphagia, developmental delay, and intellectual disability. Our case report supports the 
role of MYT1L mutations in syndromic obesity. 
Deletions of 2p25.3 disrupting MYT1L have been reported in several patients sharing 
clinical features like overweight/obesity, hyperphagia, intellectual disability, behavioral 




problems, and some dysmorphic features (Bonaglia et al., 2014; De Rocker et al., 2015; 
Doco-Fenzy et al., 2013; Stevens et al., 2011). Exome sequencing recently revealed nine 
MYT1L mutations in patients with variable intellectual disability and obesity (Blanchet et al., 
2017). All nine patients with MYT1L SNVs reported by Blanchet et al. (2017) had intellectual 
disability or developmental delay, six patients had obesity and three patients presented with 
autism spectrum disorder. Blanchet et al. (2017) performed a careful comparison of the 
clinical manifestations in patients with CNVs involving MYT1L and patients with SNVs in 
MYT1L and they observed no difference between patients with CNVs or SNVs in respect to 
obesity/overweight, hyperphagia, intellectual disability, autism, gross motor delay and speech 
delay. 
 Our patient has a similar phenotype as patients with 2p25.3 deletions features 
(Bonaglia et al., 2014; De Rocker et al., 2015; Doco-Fenzy et al., 2013; Stevens et al., 2011). 
or MYT1L SNVs (Figure 2a,b) (Blanchet et al., 2017). However, the first symptom in our 
patient was early-onset obesity starting already before the age of 2 years and continuing with 
increasing BMI Z-score up to the age of 10 years. Thereafter the patient’s BMI has to some 
extent stabilized, possibly because of the parents’ intense restriction of food intake despite 
persisting food seeking behavior and insatiable hunger. Besides obesity, our patient presented 
with developmental delay, intellectual disability and hyperactivity but brain MRI showed no 
pathology. 
MYT1L is expressed in neuronal tissues and the expression is high during fetal brain 
development (De Rocker et al., 2015). Several obesity genes are involved in the brain’s 
neuroendocrine satiety system and the hypothalamic leptin-melanocortin-SIM1 pathway is 
affected in many monogenic obesity disorders (Kaur et al., 2017). Interestingly, Blanchet et 
al. (2017) recognized MYT1L as part of the leptin-melanocortin-SIM1 pathway and oxytocin 
(OXT) downstream of MYT1L and identified OXT as an important factor in obesity 




pathogenesis. Loss of MYT1L in experimental zebrafish was related to impaired development 
of hypothalamus and reduced expression of oxytocin in the brain, providing a possible 
pathogenetic explanation for the syndromic obesity.  
Genetics are acknowledged to contribute to childhood-onset obesity and several 
monogenic forms of obesity or syndromic disorders with obesity have been described (Kaur 
et al., 2017). Severe childhood-onset obesity poses diagnostic and treatment-related 
challenges. Early intervention and diagnosis is warranted in pediatric patients with early-onset 
severe obesity and genetic causes should be considered. The Endocrine Society recommends 
genetic testing in patients with obesity onset before 5 years of age and clinical manifestations 
of genetic obesity syndrome and/or severe obesity in family (Styne et al., 2017). Identification 
of the genetic causes underlying obesity will advance future therapeutic means, support 
patients against social stigmata of obesity and enable genetic counselling. 
CONCLUSIONS 
We report on a novel frameshift variant in MYT1L as the cause of early childhood-onset 
obesity with hyperphagia and intellectual disability. Our finding further strengthens the 
hypothesis that MYT1L is a candidate gene for syndromic obesity. The identification of new 
candidate genes for severe obesity will provide insights to the pathogenic mechanisms 
involved in early-onset severe obesity. Further studies on MYT1L are warranted to expand 
our understanding of its biological function, role in appetite regulation and development of 
the syndromic features, and to identify novel therapeutic targets. 
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FIGURE 1 The patient’s BMI for age at 0-2 years (a) and 5-19 years (b). The BMI Z-scores 
have been calculated according to WHO Child Growth Standards 
(www.who.int/childgrowth/standards). 
 








FIGURE 2 (a) Schematic illustration of the MYT1L protein showing the protein’s different 
domains, previously reported pathogenic variants (Blanchet et al., 2017), and the location of 
the variant found in our patient. (b) Schematic illustration of the MYT1L gene showing the 
patient’s variant in exon 15. (c) Chromatograms of a direct sequence analysis of MYT1L gene 
exon 15 showing a novel heterozygous de novo frameshift deletion 
c.2215_2224delACGCGCTGCC, p.(Thr739Alafs*7) in a 13-year-old boy with severe obesity 
and intellectual disability. His healthy parents and sister had normal MYT1L sequences (d).  
 
